• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
VLA
Click for more information
0.00% $1.75

VIRALYTICS LIMITED - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
VLANotice of Annual General Meeting/Proxy Form12/10/11
VLAAnnual Report to shareholders12/10/11
VLASection 708a Notice07/10/11
VLAAppendix 3B07/10/11
VLACAVATAK kills cells resistant to approved melanoma drugPRICE SENSITIVE26/09/11
VLACompany Secretary Appointment/Resignation20/09/11
VLARodman and Renshaw presentation14/09/11
VLASection 708a notice14/09/11
VLAAppendix 3B14/09/11
VLASection 708A(5)(e) Notice02/09/11
VLAAppendix 3B - Partial Conversion of Convertible Note02/09/11
VLAEcho virus Chinese patent grantedPRICE SENSITIVE01/09/11
VLAAppendix 4E and statutory accountsPRICE SENSITIVE26/08/11
VLAChange of Director's Interest Notice23/08/11
VLARodman and Renshaw conference presentation18/08/11
VLAChange of Director's Interest Notices x 417/08/11
VLATrading of Post-consolidation Shares from 18 August 201116/08/11
VLACN facilty fully drawn down and appendix 3b15/08/11
VLAChange of Director's Interest Notice10/08/11
VLAChange of Constitution05/08/11
VLAShare trading on a deferred settlement basis04/08/11
VLAResults of Extraordinary General Meeting02/08/11
VLAAppendix 4C - quarterlyPRICE SENSITIVE26/07/11
VLAUpdate on CAVATAK at International Melanoma Conference13/07/11
VLACAVATAK and Lung Cancer Pre-clinical Research Presentation12/07/11
VLAPre-clinical activity of CAVATAK in pancreatic cancerPRICE SENSITIVE07/07/11
VLAChange of Director's Interest Notice04/07/11
VLALetter to Shareholders, Notice of Meeting and Proxy Form01/07/11
VLAChange of Director's Interest Notice01/07/11
VLAOpen Briefing - Update on Phase II Trials for CavatakPRICE SENSITIVE28/06/11
VLASection 708A(5)(e) Notice27/06/11
VLAAllowance of FDA Application CAVATAK Phase II Melanoma TrialPRICE SENSITIVE27/06/11
VLAAppendix 3B - Partial Conversion of Convertible Note24/06/11
VLACompany Secretary Appointment/Resignation06/06/11
VLASection 708A(5)(e) Notice30/05/11
VLAAppendix 3B - Partial Conversion of Convertible Note27/05/11
VLAASCO 2011 Presentation - CAVATAK in melanoma patients25/05/11
VLASection 708A(5)(e) Notice23/05/11
VLAAppendix 3B - Partial Conversion of Convertible Note23/05/11
VLAFDA Investigational New Drug (IND) Application UpdatePRICE SENSITIVE23/05/11
VLAPresentation at World Cancer Congress, China20/05/11
VLASection 708A(5)(e) Notice16/05/11
VLAAppendix 3B - Partial Conversion of Convertible Note16/05/11
VLASection 708A(5)(e) Notice29/04/11
VLAAppendix 3B - Partial Conversion of Convertible Note29/04/11
VLAFDA Investigational New Drug Application Update27/04/11
VLAAppendix 4C - quarterlyPRICE SENSITIVE19/04/11
VLASection 708A(5)(e) Notice19/04/11
VLAAppendix 3B - Partial Conversion of Convertible Note19/04/11
VLAPancreatic Cancer - Pre-Clinical Research Presentation08/04/11
VLASection 708A(5)(e) Notice07/04/11
VLAAppendix 3B - Partial Conversion of Convertible Note07/04/11
VLAPhase I IV Trial UpdatePRICE SENSITIVE05/04/11
VLAAppendix 4D and Half-Year Financial ReportPRICE SENSITIVE28/02/11
VLAChinese patentPRICE SENSITIVE23/02/11
VLASection 708A(5)(e) Notice14/02/11
VLAAppendix 3B - Partial Conversion of Convertible Note14/02/11
VLAPancreatic cancer researchPRICE SENSITIVE11/02/11
VLAChinese patentPRICE SENSITIVE31/01/11
VLAOncolytic Virus Portfolio Pre-clinical Research PublicationPRICE SENSITIVE27/01/11
VLASection 708A(5)(e) Notice25/01/11
VLAAppendix 3B - Partial Conversion of Convertible Note25/01/11
VLAAppendix 4C - quarterlyPRICE SENSITIVE14/01/11
VLAPublication of Pre-clinical Research13/01/11
VLAPersonnel Share Trading Policy23/12/10
VLAChange of Director's Interest Notice23/12/10
VLASection 708A(5)(e) Notice17/12/10
VLAAppendix 3B17/12/10
VLAFDA Investigational New Drug Application - Market UpdatePRICE SENSITIVE02/12/10
VLAResults of 2010 Annual General Meeting24/11/10
VLAManaging Director's Address to Shareholders - 2010 AGM24/11/10
VLASection 708A(5)(e) Notice22/11/10
VLAAppendix 3B - Partial Conversion of Convertible Note22/11/10
VLABIO-Europe 2010 - VLA Managing Director's presentation18/11/10
VLACSO presentation at International Melanoma Conference05/11/10
VLAInvestigational New Drug Application lodged with the FDAPRICE SENSITIVE03/11/10
VLAChief Scientist to address World Congress on Melanoma29/10/10
VLAModified Oncolytic virus patent grantedPRICE SENSITIVE28/10/10
VLAOctober 2010 - Shareholder Newsletter25/10/10
VLAAnnual Report to shareholders25/10/10
VLANotice of Annual General Meeting/Proxy Form25/10/10
VLASection 708A(5)(e) Notice22/10/10
VLAAppendix 3B - Partial Conversion of Convertible Note22/10/10
VLAAppendix 4C - quarterlyPRICE SENSITIVE08/10/10
VLAIntravenous trial Melanoma Breast and Prostate updatePRICE SENSITIVE06/10/10
VLADate of Annual General Meeting24/09/10
VLASection 708A(5)(e) Notice17/09/10
VLAAppendix 3B - Partial Conversion of Convertible Note17/09/10
VLAPrimary Brain Cancer15/09/10
VLAAppendix 4E and 2010 Financial ReportPRICE SENSITIVE31/08/10
VLASection 708A(5)(e) Notice18/08/10
VLAAppendix 3B - Partial Conversion of Convertible Note18/08/10
VLASection 708A(5)(e) Notice11/08/10
VLAAppendix 3B - Partial Conversion of Convertible Note11/08/10
VLAAppendix 4C - quarterlyPRICE SENSITIVE29/07/10
VLASection 708A(5)(e) Notice29/07/10
VLAAppendix 3B - Partial Conversion of Convertible Note28/07/10
VLASection 708A(5)(e) Notice08/07/10
VLAAppendix 3B - Completion of Placement08/07/10
VLAExercise of Listed Options and Placement raises $2.9mPRICE SENSITIVE02/07/10
VLANotice of Annual General Meeting/Proxy Form
12/10/11
VLAAnnual Report to shareholders
12/10/11
VLASection 708a Notice
07/10/11
VLAAppendix 3B
07/10/11
VLACAVATAK kills cells resistant to approved melanoma drug
26/09/11PRICE SENSITIVE
VLACompany Secretary Appointment/Resignation
20/09/11
VLARodman and Renshaw presentation
14/09/11
VLASection 708a notice
14/09/11
VLAAppendix 3B
14/09/11
VLASection 708A(5)(e) Notice
02/09/11
VLAAppendix 3B - Partial Conversion of Convertible Note
02/09/11
VLAEcho virus Chinese patent granted
01/09/11PRICE SENSITIVE
VLAAppendix 4E and statutory accounts
26/08/11PRICE SENSITIVE
VLAChange of Director's Interest Notice
23/08/11
VLARodman and Renshaw conference presentation
18/08/11
VLAChange of Director's Interest Notices x 4
17/08/11
VLATrading of Post-consolidation Shares from 18 August 2011
16/08/11
VLACN facilty fully drawn down and appendix 3b
15/08/11
VLAChange of Director's Interest Notice
10/08/11
VLAChange of Constitution
05/08/11
VLAShare trading on a deferred settlement basis
04/08/11
VLAResults of Extraordinary General Meeting
02/08/11
VLAAppendix 4C - quarterly
26/07/11PRICE SENSITIVE
VLAUpdate on CAVATAK at International Melanoma Conference
13/07/11
VLACAVATAK and Lung Cancer Pre-clinical Research Presentation
12/07/11
VLAPre-clinical activity of CAVATAK in pancreatic cancer
07/07/11PRICE SENSITIVE
VLAChange of Director's Interest Notice
04/07/11
VLALetter to Shareholders, Notice of Meeting and Proxy Form
01/07/11
VLAChange of Director's Interest Notice
01/07/11
VLAOpen Briefing - Update on Phase II Trials for Cavatak
28/06/11PRICE SENSITIVE
VLASection 708A(5)(e) Notice
27/06/11
VLAAllowance of FDA Application CAVATAK Phase II Melanoma Trial
27/06/11PRICE SENSITIVE
VLAAppendix 3B - Partial Conversion of Convertible Note
24/06/11
VLACompany Secretary Appointment/Resignation
06/06/11
VLASection 708A(5)(e) Notice
30/05/11
VLAAppendix 3B - Partial Conversion of Convertible Note
27/05/11
VLAASCO 2011 Presentation - CAVATAK in melanoma patients
25/05/11
VLASection 708A(5)(e) Notice
23/05/11
VLAAppendix 3B - Partial Conversion of Convertible Note
23/05/11
VLAFDA Investigational New Drug (IND) Application Update
23/05/11PRICE SENSITIVE
VLAPresentation at World Cancer Congress, China
20/05/11
VLASection 708A(5)(e) Notice
16/05/11
VLAAppendix 3B - Partial Conversion of Convertible Note
16/05/11
VLASection 708A(5)(e) Notice
29/04/11
VLAAppendix 3B - Partial Conversion of Convertible Note
29/04/11
VLAFDA Investigational New Drug Application Update
27/04/11
VLAAppendix 4C - quarterly
19/04/11PRICE SENSITIVE
VLASection 708A(5)(e) Notice
19/04/11
VLAAppendix 3B - Partial Conversion of Convertible Note
19/04/11
VLAPancreatic Cancer - Pre-Clinical Research Presentation
08/04/11
VLASection 708A(5)(e) Notice
07/04/11
VLAAppendix 3B - Partial Conversion of Convertible Note
07/04/11
VLAPhase I IV Trial Update
05/04/11PRICE SENSITIVE
VLAAppendix 4D and Half-Year Financial Report
28/02/11PRICE SENSITIVE
VLAChinese patent
23/02/11PRICE SENSITIVE
VLASection 708A(5)(e) Notice
14/02/11
VLAAppendix 3B - Partial Conversion of Convertible Note
14/02/11
VLAPancreatic cancer research
11/02/11PRICE SENSITIVE
VLAChinese patent
31/01/11PRICE SENSITIVE
VLAOncolytic Virus Portfolio Pre-clinical Research Publication
27/01/11PRICE SENSITIVE
VLASection 708A(5)(e) Notice
25/01/11
VLAAppendix 3B - Partial Conversion of Convertible Note
25/01/11
VLAAppendix 4C - quarterly
14/01/11PRICE SENSITIVE
VLAPublication of Pre-clinical Research
13/01/11
VLAPersonnel Share Trading Policy
23/12/10
VLAChange of Director's Interest Notice
23/12/10
VLASection 708A(5)(e) Notice
17/12/10
VLAAppendix 3B
17/12/10
VLAFDA Investigational New Drug Application - Market Update
02/12/10PRICE SENSITIVE
VLAResults of 2010 Annual General Meeting
24/11/10
VLAManaging Director's Address to Shareholders - 2010 AGM
24/11/10
VLASection 708A(5)(e) Notice
22/11/10
VLAAppendix 3B - Partial Conversion of Convertible Note
22/11/10
VLABIO-Europe 2010 - VLA Managing Director's presentation
18/11/10
VLACSO presentation at International Melanoma Conference
05/11/10
VLAInvestigational New Drug Application lodged with the FDA
03/11/10PRICE SENSITIVE
VLAChief Scientist to address World Congress on Melanoma
29/10/10
VLAModified Oncolytic virus patent granted
28/10/10PRICE SENSITIVE
VLAOctober 2010 - Shareholder Newsletter
25/10/10
VLAAnnual Report to shareholders
25/10/10
VLANotice of Annual General Meeting/Proxy Form
25/10/10
VLASection 708A(5)(e) Notice
22/10/10
VLAAppendix 3B - Partial Conversion of Convertible Note
22/10/10
VLAAppendix 4C - quarterly
08/10/10PRICE SENSITIVE
VLAIntravenous trial Melanoma Breast and Prostate update
06/10/10PRICE SENSITIVE
VLADate of Annual General Meeting
24/09/10
VLASection 708A(5)(e) Notice
17/09/10
VLAAppendix 3B - Partial Conversion of Convertible Note
17/09/10
VLAPrimary Brain Cancer
15/09/10
VLAAppendix 4E and 2010 Financial Report
31/08/10PRICE SENSITIVE
VLASection 708A(5)(e) Notice
18/08/10
VLAAppendix 3B - Partial Conversion of Convertible Note
18/08/10
VLASection 708A(5)(e) Notice
11/08/10
VLAAppendix 3B - Partial Conversion of Convertible Note
11/08/10
VLAAppendix 4C - quarterly
29/07/10PRICE SENSITIVE
VLASection 708A(5)(e) Notice
29/07/10
VLAAppendix 3B - Partial Conversion of Convertible Note
28/07/10
VLASection 708A(5)(e) Notice
08/07/10
VLAAppendix 3B - Completion of Placement
08/07/10
VLAExercise of Listed Options and Placement raises $2.9m
02/07/10PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
ASX Market Close: ASX closes above 8,400pts on green Wednesday | Nov 27, 2024 The ASX finished up around 8,400 points after flirting with the 8,410 level throughout the day, clearly, in a good mood.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.